Therapy Areas: Respiratory
Cantargia announces presentation of phase I clinical data on antibody CAN04 at ASCO Annual Meeting
3 June 2019 -

Cantargia AB (STO:CANTA), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Sunday that it presented new phase I clinical data on Cantargias antibody CAN04 (nidanilimab) on 31 May 2019, in an oral session at the 2019 ASCO Annual Meeting.

The phase I monotherapy data on CAN04 was presented orally in the section 'Developmental Immunotherapy and Tumour Immunobiology' by the coordinating investigator, Professor Ahmad Awada from Institut Jules Bordet in Brussels.

Reportedly, data from 22 patients show that CAN04 treatment has a good safety profile. Most patients treated got a decrease in the biomarkers IL-6 and CRP already after two weeks of therapy. Nine patients had stable disease for at least eight weeks. One patient with non-small cell lung cancer (NSCLC) progressed after 31 weeks and one patient with pancreatic cancer (PDAC) after 24 weeks.

This presentation also highlighted the rational for the ongoing clinical evaluation of CAN04 combined with chemotherapy based on synergistic effects observed in preclinical models.

According to the company, CAN04 development has expanded into the phase IIa part of the trial to further investigate CAN04 as monotherapy and in combination with standard chemotherapy.

Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both ADCC and blockade of interleukin 1 signalling. CAN04 is investigated in a phase I/IIa clinical trial, CANFOUR, examining monotherapy as well as combination with two different chemotherapy regimes in patients with NSCLC or PDAC The phase I monotherapy part also included patients with colorectal cancer.

Login
Username:

Password: